作者: Thomas Chittenden , Julianto Setiady , Peter U. Park
DOI:
关键词:
摘要: The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting growth of tumor ceils have developed and/or ALK resistance mechanisms. Methods administering patients having resistant toner cells is also disclosed.